Citations

Clear

4847 citation(s) found for "Tu, Eric".

Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines
Nehete, Pramod N. , Nehete, Bharti P. , Buchl, Stephanie J., Palmer, Donna , Montefiori, David C. , Ng, Philip , Sastry, K. Jagannadha , Barry, Michael A. , Weaver, Eric A. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Viruses | November 10, 2009 | Volume: 1 | Issue: 3 | Pages: 920-938

10.3390/v1030920 | PMID 20107521 Get It

Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5-immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.
Anemia or low hemoglobin levels preceding Parkinson disease
Savica, Rodolfo , Grossardt, Brandon R. , Carlin, J. M., Icen, M., Bower, James H., Ahlskog, J. Eric , Maraganore, Demetrius M. , Steensma, David P. , Rocca, Walter A. , Icen, M., Steensma, David P , Grossardt, Brandon R

Mayo Clinic

Neurology | October 26, 2009 | Volume: 73 | Issue: 17 | Pages: 1381-1387

10.1212/wnl.0b013e3181bd80c1 | PMID 19858460 Get It

Review Article: Palliative Oncology: Thalidomide
Prommer, Eric

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | October 20, 2009 | Volume: 27 | Issue: 3 | Pages: 198-204

10.1177/1049909109348981 | PMID 19843880 Get It

After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma. Its mechanism of action involves activation of the immune system, antiangiogenic effects, and inhibition of cytokines. Thalidomide does not interact with the cytochrome oxidase system. It is not significantly metabolized, but it does undergo nonenzymatic hydrolysis in plasma. The resulting products are inactive. Despite the potential adverse effects of peripheral neuropathy, constipation, deep vein thrombosis, somnolence, rash, and orthostatic hypotension, thalidomide is an effective first-line agent for multiple myeloma in combination with dexamethasone or melphalan and prednisone. It has also been studied in the palliative care of patients with cytokine-based syndromes such as anorexia-cachexia syndrome. This review describes its use in oncology, hematology, and palliative care.
Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and Survival
Boorjian, Stephen A. , Karnes, R. Jeffrey , Crispen, Paul L. , Rangel, Laureano J. , Bergstralh, Eric J., Blute, Michael L.

Mayo Clinic

Journal of Urology | October 17, 2009 | Volume: 182 | Issue: 6 | Pages: 2708-2715

10.1016/j.juro.2009.08.027 | PMID 19836762 Get It

The Role of Fentanyl in Cancer-Related Pain
Prommer, Eric

Mayo Clinic

Journal of Palliative Medicine | October 6, 2009 | Volume: 12 | Issue: 10 | Pages: 947-954

10.1089/jpm.2009.0051 | PMID 19807240 Get It

Thyrotropin Secretion Profiles Are Not Different in Men and Women
Roelfsema, Ferdinand , Pereira, Alberto M. , Veldhuis, Johannes D. , Adriaanse, Ria, Endert, Erik , Fliers, Eric , Romijn, Johannes A.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 22, 2009 | Volume: 94 | Issue: 10 | Pages: 3964-3967

10.1210/jc.2009-1155 | PMID 19773394 Get It

Association of C‐reactive protein with mild cognitive impairment
Roberts, Rosebud O., Geda, Yonas E. , Christianson, Teresa J., Tangalos, Eric G., Ivnik, Robert J., Petersen, Ronald C. , Knopman, David S. , Boeve, Bradley F. , Pankratz, V. Shane , Kullo, Iftikhar J. , Geda, Yonas E

Mayo Clinic

Alzheimer's & Dementia | September 13, 2009 | Volume: 5 | Issue: 5 | Pages: 398-405

10.1016/j.jalz.2009.01.025 | PMID 19751919 Get It

Background Inflammation is proposed to play a role in the development of Alzheimer's disease, and may also be involved in the pathogenesis of mild cognitive impairment (MCI). This study examined the association of inflammatory markers in serum or plasma with prevalent MCI and MCI subtypes in a population‐based sample. Methods Olmsted County, MN, residents aged 70–89 years on October 1, 2004, were evaluated using the Clinical Dementia Rating Scale, a neurological evaluation, and neuropsychological testing. Information ascertained for each participant was reviewed by an expert panel of neuropsychologists, physicians, and nurses, and a diagnosis of normal cognition, MCI, or dementia was made by consensus. C‐reactive protein (CRP), interleukin‐6 (IL‐6), tumor necrosis alpha (TNFα), and adiponectin were measured at baseline. Results Among 313 subjects with MCI and 1570 cognitively normal subjects, a CRP level in the upper quartile (>3.3 mg/L) was significantly associated with MCI (odds ratio [OR], 1.42; 95% confidence interval [CI], 1.00–2.01) and with nonamnestic MCI (OR, 2.05; 95% CI, 1.12–3.78) after adjusting for age, sex, and years of education. However, there was no association with amnestic MCI (OR, 1.21; 95% CI, 0.81–1.82). No association was observed with the other inflammatory markers. Conclusions Plasma CRP is associated with prevalent MCI and with nonamnestic MCI in elderly, nondemented persons in a population‐based setting. These findings suggest the involvement of inflammation in the pathogenesis of MCI.
Risk of Fracture After Single Fraction Image-Guided Intensity-Modulated Radiation Therapy to Spinal Metastases
Rose, Peter S. , Laufer, Ilya , Boland, Patrick J. , Hanover, Andrew, Bilsky, Mark H. , Yamada, Josh, Lis, Eric

Mayo Clinic

Journal of Clinical Oncology | September 9, 2009 | Volume: 27 | Issue: 30 | Pages: 5075-5079

10.1200/jco.2008.19.3508 | PMID 19738130 Get It

Purpose Single-fraction image-guided intensity-modulated radiation therapy (IG-IMRT) allows for tumoricidal treatment of traditionally radioresistant cancers while sparing critical adjacent structures. Risk of vertebral fracture after IG-IMRT for spinal metastases has not been defined. Patients and Methods We evaluated 62 consecutive patients undergoing single fraction IG-IMRT at 71 sites for solid organ metastases. A neuroradiologist and three spine surgeons evaluated prospectively obtained magnetic resonance/computed tomography (CT) imaging studies for post-treatment fracture development and tumor recurrence. Results Fracture progression was noted in 27 vertebrae (39%). Multivariate logistic regression analysis showed that CT appearance, lesion location, and percent vertebral body involvement independently predicted fracture progression. Lesions located between T10 and the sacrum were 4.6 times more likely to fracture than were lesions above T10 (95% CI, 1.1 to 19.7). Lytic lesions were 6.8 times more likely to fracture than were sclerotic and mixed lesions (95% CI, 1.4 to 33.3). As percent vertebral body involvement increased, odds of fracture also increased. Patients with fracture progression had significantly higher narcotic use, change in Karnofsky performance score, and a strong trend toward higher pain scores. Local tumor progression occurred in seven patients and contributed to one fracture. Obesity, posterior element involvement, bisphosphonate use, and local kyphosis did not confer increased risk. Conclusion Vertebral fracture is common after single fraction IG-IMRT for metastatic spine lesions. Lytic disease involving more than 40% of the vertebral body and location at or below T10 confer a high risk of fracture, the presence of which yields significantly poorer clinical outcomes. These results may help clinicians identify high-risk patients who would benefit from prophylactic vertebro- or kyphoplasty.
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for P
Micallef, Ivana N. , Stiff, Patrick J. , Bolwell, Brian J., Jacobsen, Eric D. , Nademanee, Auayporn, McCarty, John M. , Bridger, Gary, Calandra, Gary, DiPersio, John F. , Maziarz, Richard Thomas

Mayo Clinic

Journal of Clinical Oncology | August 31, 2009 | Volume: 27 | Issue: 28 | Pages: 4767-4773

10.1200/jco.2008.20.7209 | PMID 19720922 Get It

Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients. Patients and Methods This is a phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study. Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible. Patients received granulocyte colony-stimulating factor (G-CSF; 10 μg/kg) subcutaneously daily for up to 8 days. Beginning on evening of day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 μg/kg) or placebo subcutaneously. Starting on day 5, patients began daily apheresis for up to 4 days or until ≥ 5 × 10 6 CD34+ cells/kg were collected. The primary end point was the percentage of patients who collected ≥ 5 × 10 6 CD34+ cells/kg in 4 or fewer apheresis days. Results This report presents all data for all patients (n = 298) through 12 months follow-up. Eighty-nine (59%) of 150 patients in the plerixafor group and 29 (20%) of 148 patients in the placebo group met the primary end point (P < .001). One hundred thirty-five patients (90%) in plerixafor group and 82 patients (55%) in placebo group underwent transplantation after initial mobilization. Median time to engraftment was similar in both groups. The most common plerixafor-associated adverse events were GI disorders and injection site reactions. Conclusion Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
Fibroepithelial Polyps of the Ureter: A Single-Institutional Experience
Childs, M. Adam, Umbreit, Eric , Krambeck, Amy E. , Sebo, Thomas J., Patterson, David E., Gettman, Matthew T.

Mayo Clinic

Journal of Endourology | August 28, 2009 | Volume: 23 | Issue: 9 | Pages: 1415-1419

10.1089/end.2009.0403 | PMID 19715398 Get It